RETRACTED ARTICLE:Betulin inhibits lung carcinoma proliferation through activation of AMPK signaling

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11153-11158

  Li, Xian Dong ^a   Zhang, Yi Jie ^a   Han, Ji Chang ^a  

^a HENAN UNIVERSITY   (China)

Author keywords

AMPK signaling; Betulin; Lung carcinoma; Proliferation

Indexed keywords

BETULIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; MTOR PROTEIN, HUMAN; S6 KINASE; TARGET OF RAPAMYCIN KINASE; TRITERPENE;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRITERPENES; TUMOR CELLS, CULTURED;

EID: 84927799476     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2426-7     Document Type: TB

References (23)

1. Keith RL, Miller YE. Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol. 2013;10:334–43.
2. Berkovich L, Ron I, Earon G, Abu-Ghanem S, Rimmon A, Lev-Ari S. The role of medicinal herbs with anti-inflammatory properties in prevention and treatment of cancer. Harefuah. 2012;151(629-632):654.
3. McLeod HL. Cancer pharmacogenomics: early promise, but concerted effort needed. Science. 2013;339:1563–6.
4. Ali R, Mirza Z, Ashraf GM, Kamal MA, Ansari SA, Damanhouri GA, et al. New anticancer agents: recent developments in tumor therapy. Anticancer Res. 2012;32:2999–3005.
5. Dehelean CA, Feflea S, Molnar J, Zupko I, Soica C. Betulin as an antitumor agent tested in vitro on a431, hela and mcf7, and as an angiogenic inhibitor in vivo in the cam assay. Nat Prod Commun. 2012;7:981–5.
6. Li Y, He K, Huang Y, Zheng D, Gao C, Cui L, et al. Betulin induces mitochondrial cytochrome c release associated apoptosis in human cancer cells. Mol Carcinog. 2010;49:630–40.
7. Rzeski W, Stepulak A, Szymański M, Juszczak M, Grabarska A, Sifringer M, et al. Betulin elicits anti-cancer effects in tumour primary cultures and cell lines in vitro. Basic Clin Pharmacol Toxicol. 2009;105:425–32.
8. Kommera H, Kaluđerović GN, Kalbitz J, Paschke R. Lupane triterpenoids-betulin and betulinic acid derivatives induce apoptosis in tumor cells. Invest New Drugs. 2011;29:266–72.
9. Pyo JS, Roh SH, Kim DK, Lee JG, Lee YY, Hong SS, et al. Anti-cancer effect of Betulin on a human lung cancer cell line: a pharmacoproteomic approach using 2 D SDS PAGE coupled with nano-HPLC tandem mass spectrometry. Planta Med. 2009;75:127–31.
10. Wang HM, Soica CM, Wenz G. A comparison investigation on the solubilization of betulin and betulinic acid in cyclodextrin derivatives. Nat Prod Commun. 2012;7:289–91.
11. Dehaen W, Mashentseva AA, Seitembetov TS. Allobetulin and its derivatives: synthesis and biological activity. Molecules. 2011;16:2443–66.
12. Alakurtti S, Makela T, Koskimies S, Yli-Kauhaluoma J. Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci. 2006;29:1–13.
13. Krycer JR, Phan L, Brown AJ. A key regulator of cholesterol homoeostasis, srebp-2, can be targeted in prostate cancer cells with natural products. Biochem J. 2012;446:191–201.
14. Shackelford DB, Shaw RJ. The lkb1-ampk pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563–75.
15. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7:277–85.
16. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67:6745–52.
17. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, et al. Important role of the lkb1-ampk pathway in suppressing tumorigenesis in pten-deficient mice. Biochem J. 2008;412:211–21.
18. Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo llc1 carcinoma growth. Endocr Relat Cancer. 2008;15:833–9.
19. Lai HC, Singh NP, Sasaki T. Development of artemisinin compounds for cancer treatment. Invest New Drugs. 2013;31:230–46.
20. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an amp kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269–73.
21. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011;71:4366–72.
22. Tang JJ, Li JG, Qi W, Qiu WW, Li PS, Li BL, et al. Inhibition of srebp by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab. 2011;13:44–56.
23. Wan Y, Jiang S, Lian LH, Bai T, Cui PH, Sun XT, et al. Betulinic acid and betulin ameliorate acute ethanol-induced fatty liver via tlr4 and stat3 in vivo and in vitro. Int Immunopharmacol. 2013;17:184–90.